# US 2021/0069306 A1 · Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069306 A1
- Document ID: US20210069306A1
- Status: Published application
- Kind: A1
- Application number: 16/994,573
- Filed: 2020-08-15
- Published: 2021-03-11
- Earliest claimed: 2019-08-15
- Applicants: Catalyst Biosciences, Inc.
- Inventors: Grant E. BLOUSE; Tom KNUDSEN; Howard LEVY
- Web page: https://patentgrep.com/patent/US20210069306A1

## CPC

- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C07K 16/36: against blood coagulation factors
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Y 304/21021: Coagulation factor VIIa (3.4.21.21)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/31: Combination therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided herein are modified FVII polypeptides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.

## Claims

### Claim 1

A method of treating a bleeding event in a subject, comprising subcutaneously administering to the subject a dose of a modified Factor VIIa comprising modifications at least at a position corresponding to position 286 and at a position corresponding to position 298 in a FVII polypeptide comprising the sequence of amino acids set forth in SEQ ID NO: 3 or in a corresponding residue in a FVII polypeptide, wherein:
the modification at position 286 is an amino acid replacement with Arg (R);
the modification at position 298 is an amino acid replacement with Gln (Q);
the subcutaneous administration of the modified FVIIa has increased activity or potency; and
a dose of the modified FVIIa is administered subcutaneously within about 5 or 4 or 3 or 2 or 1 or fewer hours or minutes before and/or after the bleeding event, whereby the amount of bleeding is reduced or stopped or the cause of the bleed is corrected or is healed.

### Claim 2 (depends on 1)

The method of claim 1, the modified FVIIa further comprising a modification at a position corresponding to position 128 in the FVII polypeptide having the sequence of amino acids set forth in SEQ ID NO: 3, wherein:
the modification at position 128 is an amino acid replacement with Asn (N).

### Claim 3 (depends on 2)

The method of claim 2, the modified FVIIa further comprising a modification at a position corresponding to position 129 and in the FVII polypeptide having the sequence of amino acids set forth in SEQ ID NO: 3, wherein:
the modification at position 129 is Ala (A).

### Claim 4 (depends on 1)

The method of claim 1, wherein the dose of the modified FVIIa is administered subcutaneously within about 5 or 4 or 3 or 2 or 1 or fewer hours or minutes before or after the bleeding event.

### Claim at position 5

5-27. (canceled)

### Claim 28 (depends on 1)

The method of claim 1, wherein:
the bleeding is episodic or predictable by the subject; and
the subject is treated with a subcutaneous dose of the modified FVIIa before the bleeding starts.

### Claim 29 (depends on 1)

The method of claim 1, wherein:
the bleeding event results from trauma or injury; and
the subject is treated with a subcutaneous dose of the modified FVIIa 15 minutes, 1, 2, 3, or 4 hours after the bleeding event.

### Claim 30 (depends on 1)

The method of claim 1, wherein:
the subject has a hemophilia or other bleeding disorder or condition, and is undergoing surgery;
a dose of the modified FVIIa is subcutaneously administered 5, 4, 3, 2, 1 hours or less before surgery;
the subject is treated with a FVIIa intravenously during surgery; and
a dose of the modified FVIIa is subcutaneously administered at least one time following surgery until there is no bleeding and/or risk of bleeding or until the subject is healed or the cause is corrected.

### Claim at position 9

31-41. (canceled)

### Claim 42 (depends on 1)

The method of claim 1, wherein:
the bleed is episodic or predictable; and
the subject is pre-treated prior to the bleeding, and wherein the pre-treatment is effected about 4 hours or less, 3 hours or less, 2 hours or less, 1 hour or less, or at least 15 minutes before the bleed.

### Claim at position 11

43-45. (canceled)

### Claim 46 (depends on 1)

The method of claim 1, wherein the bleeding is the result of any one or more of surgery, trauma, injury, a wound, menstrual bleeding, a joint bleed, trauma, dental extraction, or bleeding gums.

### Claim at position 13

47-50. (canceled)

### Claim 51 (depends on 1)

The method of claim 1, wherein a dose or doses of the modified FVIIa is/are administered subcutaneously before the bleeding or after the bleeding starts.

### Claim at position 15

52-53. (canceled)

### Claim 54 (depends on 1)

The method of claim 1, wherein the modified FVIIa is administered subcutaneously a plurality of times until the bleeding stops or the wound heals or bleeding is corrected.

### Claim 55 (depends on 1)

The method of claim 1, wherein a single dose of the modified FVIIa is from about 10 μg/kg to 30 μg/kg, 10 μg/kg to 60 μg/kg, 10 μg/kg to 90 μg/kg, 10 μg/kg to 120 μg/kg, 30 μg/kg to 60 μg/kg, 30 μg/kg to 90 μg/kg, 30 μg/kg to 120 μg/kg, 10 μg/kg to 500 μg/kg, or 15 μg/kg to 400 μg/kg, or 15 μg/kg to 350 μg/kg, or 20 μg/kg to 400 μg/kg, or 20 μg/kg to 350 μg/kg, or 30 μg/kg to 350 μg/kg, or 25 μg/kg to 350 μg/kg, based on the weight of the treated subject.

### Claim at position 18

56-60. (canceled)

### Claim 61 (depends on 1)

The method of claim 1, wherein a single subcutaneous dose of the modified FVIIa is in a volume of about 1 mL to 2 mL, or 1.25 mL to 1.5 mL, or 1 mL to 10 mL.

### Claim 62 (depends on 1)

The method of claim 1, further comprising administering any one or more of an additional coagulant treatment or factor, an anti-tissue factor pathway inhibitor (TFPI) antibody, and an RNA interference (RNAi) therapeutic targeting antithrombin (AT).

### Claim at position 21

63-68. (canceled)

### Claim 69 (depends on 1)

The method of claim 1, wherein the subject has any one or more of blood coagulation disorders, hematologic disorders, hemorrhagic disorders, hemophilia A, hemophilia B, hemophilia A with inhibitors, hemophilia B with inhibitors, Factor VII deficiency, Glanzmann thrombasthenia, and acquired hemophilia, and/or wherein the subject is taking anti-coagulant therapy, and/or wherein the subject has autoantibodies to factor VIII or factor IX, and other bleeding disorders.

### Claim at position 23

70-71. (canceled)

### Claim 72 (depends on 69)

The method of claim 69, wherein the subject has hemophilia, and the hemophilia is congenital or acquired.

### Claim at position 25

73-74. (canceled)

### Claim 75 (depends on 1)

The method of claim 1, wherein a single subcutaneous dose of the modified FVIIa is about 60 μg/kg to about 120 μg/kg, or about 60 μg/kg, or about 10 to about 20 μg/kg, or about 10 μg/kg, or about 20 μg/kg based on the weight of the treated subject.

### Claim at position 27

76-83. (canceled)

### Claim 84 (depends on 1)

The method of claim 1, wherein the modified FVIIa has a potency greater than the FVIIa of SEQ ID NO: 3.

### Claim 85 (depends on 1)

The method of claim 1, wherein the modified FVIIa has increased coagulant activity, compared to wild-type FVIIa of SEQ ID NO: 3, in the absence of tissue factor and/or in the presence of tissue factor.

### Claim 86

(canceled)

### Claim 87 (depends on 186)

The method of claim 186, wherein the modified FVIIa has kcat/km in a tissue-factor dependent assay that is greater than 100%, 150%, 200%, or 250% or more than unmodified FVIIa (SEQ ID NO: 3) in the same assay and/or wherein the modified FVIIa has coagulation activity that is at least 1.5, or 3, or 4, or 5 times the activity of unmodified FVIIa of SEQ ID NO: 3 in the same assay.

### Claim at position 32

88-90. (canceled)

### Claim 91 (depends on 1)

The method of claim 1, wherein coagulation activity of the modified FVIIa polypeptide is at least 110%, 150%, 200%, 250%, 300%, 400%, 500% or more of the coagulation activity of an unmodified FVIIa polypeptide that has the primary amino acid sequence set forth in SEQ ID NO: 3.

### Claim 92 (depends on 1)

The method of claim 1, wherein the modified FVIIa has any one or more of increased serum half-life, an increased terminal elimination half-life, greater coagulation activity, and greater potency compared to an unmodified FVIIa that has the primary amino acid sequence set forth in SEQ ID NO: 3.

### Claim 93

(canceled)

### Claim 94 (depends on 1)

The method of claim 1, wherein:
the modified FVIIa polypeptide, when in an activated form, exhibits procoagulant activity, wherein:
the procoagulant activity is greater than procoagulant activity of a FVIIa polypeptide having the primary amino acid sequence set forth in SEQ ID NO: 3.

### Claim 95

(canceled)

### Claim 96 (depends on 1)

The method of claim 1, wherein the modified FVIIa polypeptide is two-chain activated Factor VII (FVIIa) polypeptide comprising the amino acid sequence of SEQ ID NO: 280 or comprising the amino acid sequence of SEQ ID NO: 138 cleaved between the arginine at position 152 and the isoleucine at position 153.

### Claim 97

(canceled)

### Claim 98 (depends on 1)

The method of claim 1, wherein the modified FVIIa polypeptide has at least 90% amino acid sequence identity to SEQ ID NO: 280, wherein the amino acids corresponding to positions 128, 129, 286 and 298 of SEQ ID NO: 280 are invariant.

### Claim 99 (depends on 96)

The method of claim 96, wherein the first and second chains of the two-chain polypeptide consist respectively of amino acids 1-152 and 153-406 of SEQ ID NO: 280.

### Claim 100 (depends on 1)

The method of claim 1, wherein the modified FVIIa polypeptide comprises one or more amino acid modification(s) that increases resistance to antithrombin-III, increases binding and/or affinity to phospholipids, increases affinity for tissue factor, increases intrinsic activity, increases TF-dependent activity, increases coagulant activity, alters the conformation of the polypeptide to alter zymogenicity, increases catalytic or coagulant activity by shifting the equilibrium between highly active and less active FVIIa conformations in favor of the highly active conformations, increases resistance to proteases, decreases glycosylation, increases glycosylation, reduces immunogenicity, increases stability, and/or facilitates chemical group linkage.

### Claim 101 (depends on 1)

The method of claim 1, wherein the primary sequence of the unmodified FVIIa polypeptide consists of the sequence of amino acids set forth in SEQ ID NO: 3.

### Claim 102 (depends on 1)

The method of claim 1, wherein the modified FVIIa polypeptide is post-translationally modified, wherein a post-translational modification is any one or more of O-linked glycosylation, N-linked glycosylation, carboxylation of glutamic acid to γ-carboxyglutamic acid, and hydroxylation of aspartic acid to β-hydroxyaspartic acid.

### Claim at position 45

103-108. (canceled)

### Claim 109 (depends on 1)

The method of claim 1, wherein the subcutaneous administration of the modified FVIIa has increased terminal elimination half-life compared to an intravenous administration of the modified FVIIa.

### Claim 110 (depends on 1)

The method of claim 1, wherein a dose of the modified FVIIa is administered in a multiple dosing regimen, and wherein at least one dose of the multiple dosing regimen comprises about 30 μg/kg, about 45 μg/kg, about 60 μg/kg, about 90 μg/kg, or about 120 μg/kg of body weight of the subject.

### Claim at position 48

111-127. (canceled)

### Claim 128 (depends on 1)

The method of claim 1, wherein the subcutaneous administration of the modified FVIIa has an activity or potency greater than an intravenous administration of the modified FVIIa polypeptide and/or greater than an intravenous administration of an FVIIa polypeptide that is unmodified and/or greater than a subcutaneous administration of an FVIIa polypeptide that is unmodified.

### Claim at position 50

129-131. (canceled)

### Claim 132 (depends on 1)

The method of claim 1, wherein the modified FVIIa comprises the amino acid sequence set forth in SEQ ID NO: 280 or SEQ ID NO: 138.

### Claim 133

A method of providing an on-demand treatment to a subject experiencing a bleed or to a subject likely to experience a bleed, comprising administering to the subject a subcutaneous dose of a modified FVIIa comprising modifications at least at a position corresponding to position 286 and at a position corresponding to position 298 in a FVII polypeptide comprising the sequence of amino acids set forth in SEQ ID NO: 3 or in a corresponding residue in a FVII polypeptide, wherein:
the modification at position 286 is an amino acid replacement with Arg (R);
the modification at position 298 is an amino acid replacement with Gln (Q); and
the dose is about 10 to about 120 μg/kg of body weight of the subject.

### Claim 134 (depends on 133)

The method of claim 133, the modified FVIIa further comprising a modification at a position corresponding to position 128 in the FVII polypeptide having the sequence of amino acids set forth in SEQ ID NO: 3, wherein
the modification at position 128 is an amino acid replacement with Asn (N).

### Claim 135 (depends on 134)

The method of claim 134, the modified FVIIa further comprising a modification at a position corresponding to position 129 in the FVII polypeptide having the sequence of amino acids set forth in SEQ ID NO: 3, wherein:
the modification at position 129 is Ala (A).

### Claim 136 (depends on 133)

The method of claim 133, wherein the subcutaneous dose of a modified FVIIa is administered in a multiple dosing regimen, and wherein each dose of the multiple dosing regimen occurs about 2 to about 6 hours apart for a predetermined time period.

### Claim at position 56

137-143. (canceled)

### Claim 144 (depends on 1)

The method of claim 1, wherein the subject has any one or more of hemophilia A, hemophilia B, hemophilia A with inhibitors, hemophilia B with inhibitors, hemophilia C, Factor VII deficiency, Glanzmann thrombasthenia, acquired hemophilia, or is taking anti-coagulant therapy.

### Claim 145

(canceled)

### Claim 146 (depends on 144)

The method of claim 144, wherein the subject has a hemophilia, and the hemophilia is congenital or acquired.

### Claim at position 60

147-151. (canceled)

### Claim 152 (depends on 133)

The method of claim 133, wherein the on-demand treatment comprises administering the treatment to a subject experiencing a bleed or a subject likely to experience a bleed.

### Claim 153 (depends on 152)

The method of claim 152, wherein the subject is experiencing a bleed and the subcutaneous dose is administered about 1 minute to about 1 hour, or about 2, or about 3, or about 4 hours after onset of the bleed, or wherein the subject is likely to experience a bleed and the subcutaneous dose is administered about 1 minute to about 1 hour, or about 2, or about 3, or about 4, or about 5, or about 6, or about 7 hours before the likelihood of a bleed.

### Claim at position 63

154-162. (canceled)

### Claim 163 (depends on 133)

The method of claim 133, wherein the subcutaneous administration of the modified FVIIa has an activity or potency greater than an intravenous administration of the modified FVIIa polypeptide, and/or greater than an intravenous administration of an FVIIa polypeptide that is unmodified, and/or greater than a subcutaneous administration of an FVIIa polypeptide that is unmodified.

### Claim at position 65

164-166. (canceled)

### Claim 167 (depends on 133)

The method of claim 133, wherein the modified FVIIa polypeptide is two-chain activated Factor VII (FVIIa) polypeptide comprising the amino acid sequence of SEQ ID NO: 280 cleaved between the arginine at position 152 and the isoleucine at position 153.

### Claim 168

A pharmaceutical composition for a single dosage subcutaneous administration, comprising a single therapeutically effective dose of a modified FVIIa in a pharmaceutically acceptable carrier for subcutaneous administration for an on-demand treatment of a bleed; wherein the modified FVIIa comprises modifications at least at a position corresponding to position 286 and at a position corresponding to position 298 in a FVII polypeptide comprising the sequence of amino acids set forth in SEQ ID NO: 3 or in a corresponding residue in a FVII polypeptide, wherein:
the modification at position 286 is an amino acid replacement with Arg (R);
the modification at position 298 is an amino acid replacement with Gln (Q); and
the modified FVIIa has increased activity or potency.

### Claim 169 (depends on 168)

The pharmaceutical composition of claim 168, wherein the modified FVIIa has an activity or potency greater than an intravenous administration of the modified FVIIa polypeptide, and/or greater than an intravenous administration of an FVIIa polypeptide that is unmodified, and/or greater than a subcutaneous administration of an FVIIa polypeptide that is unmodified.

### Claim at position 69

170-171. (canceled)

### Claim 172 (depends on 168)

The pharmaceutical composition of claim 168, the modified FVIIa further comprising modifications at a position corresponding to position 128 in the FVII polypeptide having the sequence of amino acids set forth in SEQ ID NO: 3, wherein:
the modification at position 128 is an amino acid replacement with Asn (N).

### Claim 173 (depends on 172)

The pharmaceutical composition of claim 172, the modified FVIIa further comprising modifications at a position corresponding to position 128 and at a position corresponding to position 129 in the FVII polypeptide having the sequence of amino acids set forth in SEQ ID NO: 3, wherein:
the modification at position 128 is an amino acid replacement with Asn (N); and
the modification at position 129 is Ala (A).

### Claim 174 (depends on 168)

The pharmaceutical composition of claim 168, wherein the amount of modified FVIIa is from 100 μg to 35 mg in a volume of 1 ml to 10 ml.

### Claim at position 73

175-178. (canceled)

### Claim 179 (depends on 168)

A container, comprising the pharmaceutical composition of claim 168, wherein the container is a syringe or injector pen and wherein the pharmaceutical composition is lyophilized.

### Claim at position 75

180-182. (canceled)

### Claim 183 (depends on 168)

An on-demand method of treating a bleed in a subject, comprising subcutaneously administering to the subject the pharmaceutical composition of claim 168.

### Claim 184

(canceled)
